Patients Coming Off Weight-Loss Medications Put On Pounds at a Quadrupled Rate Than Those on Conventional Diets

New research indicates that patients who discontinue new slimming jabs like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who halt conventional diet and exercise programs.

Research printed in a leading health publication shows that while obese individuals frequently drop substantial amounts of their body weight while on the medication, the weight is regained at an estimated rate of 0.8 kg per month once they quit.

"Users buying such treatments need to be aware of the risk of rapid weight regain when the medication concludes," cautioned expert Dr. Susan Jebb.

This pace of regain implies a return to pre-treatment mass within about 18 months.

Comparing Approaches

The research, which looked at dozens of studies involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with older methods.

The team emphasize that people who lose weight through lifestyle changes alone usually experience a slower creep back—approximately 100 grams monthly—post-intervention.

The Reason for the Fast Rebound

Doctors believe the mode of action of the injections is key to understanding the heightened rebound.

GLP-1 drugs imitate a natural hormone called GLP-1, which moderates hunger.

"Artificially providing the hormone concentrations far above than the body's typical production might result in the body to generate a reduced amount of its endogenous hormone, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.

"Stopping of this hormone supplement leads to appetite is uncontrolled, making excessive eating much more probable."

A Lifelong Disease?

Health authorities suggest the injections for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.

Professionals contend that, considering the likelihood of weight regain, the therapy might need to be ongoing.

This opinion is echoed by drug manufacturers, who state that the findings "underscore the long-term nature of obesity," similar to managing conditions like high blood pressure.

User Experiences

Individuals who have come off the medication report a powerful return of cravings.

"It was like something activating and I was suddenly extremely hungry," recalled one woman.

This challenge is worsened if patients have not adopted lasting lifestyle or habit modifications during therapy.

Significant Adoption

Survey data suggest that millions of people in the UK have tried these injections in the past year, with demand continuing to grow.

• Adoption is more common among women compared to males.
• The middle-aged age group shows the greatest usage rates.
• Many obtain the medications through private prescriptions rather than public health services.

In conclusion, clinicians caution that while the jabs are powerful tools for weight loss, they are not a permanent cure and maintained weight loss hinges on integrated lifestyle changes.